{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:16:09Z","timestamp":1790788569816,"version":"4.1.0"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T00:00:00Z","timestamp":1298332800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1038\/nrneph.2011.12","type":"journal-article","created":{"date-parts":[[2011,2,22]],"date-time":"2011-02-22T14:05:10Z","timestamp":1298383510000},"page":"226-235","source":"Crossref","is-referenced-by-count":81,"title":["Antibiotic dosing in critically ill patients with acute kidney injury"],"prefix":"10.1038","volume":"7","author":[{"given":"Rachel F.","family":"Eyler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,2,22]]},"reference":[{"key":"BFnrneph201112_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1001\/jama.294.7.813","volume":"294","author":"S Uchino","year":"2005","unstructured":"Uchino, S. et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 294, 813\u2013818 (2005).","journal-title":"JAMA"},{"key":"BFnrneph201112_CR2","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1097\/CCM.0b013e3181aab3d0","volume":"37","author":"G Choi","year":"2009","unstructured":"Choi, G. et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit. Care Med. 37, 2268\u20132282 (2009).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR3","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/jac\/dkp302","volume":"64","author":"AM Li","year":"2009","unstructured":"Li, A. M. et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J. Antimicrob. Chemother. 64, 929\u2013937 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrneph201112_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccc.2006.02.011","volume":"22","author":"BA Boucher","year":"2006","unstructured":"Boucher, B. A., Wood, G. C. & Swanson, J. M. Pharmacokinetic changes in critical illness. Crit. Care Clin. 22, 255\u2013271 (2006).","journal-title":"Crit. Care Clin."},{"key":"BFnrneph201112_CR5","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4037\/ajcc1997.6.3.204","volume":"6","author":"JK Stechmiller","year":"1997","unstructured":"Stechmiller, J. K., Treloar, D. & Allen, N. Gut dysfunction in critically ill patients: a review of the literature. Am. J. Crit. Care 6, 204\u2013209 (1997).","journal-title":"Am. J. Crit. Care"},{"key":"BFnrneph201112_CR6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1211\/002235702982","volume":"55","author":"H Okabe","year":"2003","unstructured":"Okabe, H. et al. The increased intestinal absorption rate is responsible for the reduced hepatic first-pass extraction of propranolol in rats with cisplatin-induced renal dysfunction. J. Pharm. Pharmacol. 55, 479\u2013486 (2003).","journal-title":"J. Pharm. Pharmacol."},{"key":"BFnrneph201112_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1042\/cs0590317","volume":"5","author":"CA Hughes","year":"1980","unstructured":"Hughes, C. A. & Dowling, R. H. Speed of onset of adaptive mucosal hypoplasia and hypofunction in the intestine of parenterally fed rats. Clin. Sci. (Lond.) 5, 317\u2013327 (1980).","journal-title":"Clin. Sci. (Lond.)"},{"key":"BFnrneph201112_CR8","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/088453368600100506","volume":"1","author":"KE Fagerman","year":"1986","unstructured":"Fagerman, K. E., McGuigan, D. & Pixley, B. Potential interaction between enteral feeding solutions and oral tetracycline. Nutr. Clin. Pract. 1, 257\u2013258 (1986).","journal-title":"Nutr. Clin. Pract."},{"key":"BFnrneph201112_CR9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1177\/014860710002400142","volume":"24","author":"DH Wright","year":"2000","unstructured":"Wright, D. H., Pietz, S. L., Konstantinides, F. N. & Rotschafer, J. C. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. J. Parenter. Enteral Nutr. 24, 42\u201348 (2000).","journal-title":"J. Parenter. Enteral Nutr."},{"key":"BFnrneph201112_CR10","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1128\/AAC.38.9.2101","volume":"38","author":"BA Mueller","year":"1994","unstructured":"Mueller, B. A., Brierton, D. G., Abel, S. R. & Bowman, L. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob. Agents Chemother. 38, 2101\u20132105 (1994).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1365-2036.1993.tb00103.x","volume":"7","author":"SG Lim","year":"1993","unstructured":"Lim, S. G., Sawyerr, A. M., Hudson, M., Sercombe, J. & Pounder, E. Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity. Aliment. Pharmacol. Ther. 7, 317\u2013321 (1993).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BFnrneph201112_CR12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/MAT.0b013e3181de35e4","volume":"56","author":"T F\u00fcl\u00f6p","year":"2010","unstructured":"F\u00fcl\u00f6p, T. et al. Volume-related weight gain and subsequent mortality in acute renal failure patients treated with continuous renal replacement therapy. ASAIO J. 56, 333\u2013337 (2010).","journal-title":"ASAIO J."},{"key":"BFnrneph201112_CR13","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/nrneph.2009.138","volume":"5","author":"RW Schrier","year":"2009","unstructured":"Schrier, R. W. AKI: fluid overload and mortality. Nat. Rev. Nephrol. 5, 485 (2009).","journal-title":"Nat. Rev. Nephrol."},{"key":"BFnrneph201112_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0002-9343(02)01230-5","volume":"113","author":"RL Mehta","year":"2002","unstructured":"Mehta, R. L. et al. Nephrology consultation in acute renal failure: does timing matter? Am. J. Med. 113, 527\u2013528 (2002).","journal-title":"Am. J. Med."},{"key":"BFnrneph201112_CR15","first-page":"455","volume":"18","author":"KD Edwards","year":"1959","unstructured":"Edwards, K. D. Creatinine space as a measure of total body water in anuric subjects, estimated after single injection and haemodialysis. Clin. Sci. 18, 455\u2013464 (1959).","journal-title":"Clin. Sci."},{"key":"BFnrneph201112_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","volume":"37","author":"JA Roberts","year":"2009","unstructured":"Roberts, J. A. & Lipman, J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37, 840\u2013850 (2009).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR17","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1034\/j.1399-6576.1999.430707.x","volume":"43","author":"GJ Tang","year":"1999","unstructured":"Tang, G. J., Tang, J. J., Lin, B. S., Kong, C. W. & Lee, T. Y. Factors affecting gentamicin pharmacokinetics in septic patients. Acta Anaesthesiol. Scand. 43, 726\u2013730 (1999).","journal-title":"Acta Anaesthesiol. Scand."},{"key":"BFnrneph201112_CR18","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1128\/AAC.00222-10","volume":"54","author":"JA Roberts","year":"2010","unstructured":"Roberts, J. A. et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob. Agents Chemother. 54, 3635\u20133640 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR19","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/BF01706354","volume":"16","author":"C Triginer","year":"1990","unstructured":"Triginer, C. et al. Gentamicin volume of distribution in critically ill septic patients. Intensive Care Med. 16, 303\u2013306 (1990).","journal-title":"Intensive Care Med."},{"key":"BFnrneph201112_CR20","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1592\/phco.27.8.1081","volume":"27","author":"MP Pai","year":"2007","unstructured":"Pai, M. P. & Bearden, D. T. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27, 1081\u20131091 (2007).","journal-title":"Pharmacotherapy"},{"key":"BFnrneph201112_CR21","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(09)60743-1","volume":"375","author":"ME Falagas","year":"2010","unstructured":"Falagas, M. E. & Karageorgopoulos, D. E. Adjustment of dosing of antimicrobial agents for bodyweight in adults. Lancet 375, 248\u2013251 (2010).","journal-title":"Lancet"},{"key":"BFnrneph201112_CR22","doi-asserted-by":"publisher","first-page":"20S","DOI":"10.1016\/S0002-9610(96)00346-7","volume":"172","author":"D Fry","year":"1996","unstructured":"Fry, D. The importance of antibiotic pharmacokinetics in critical illness. Am. J. Surg. 172, 20S\u201325S (1996).","journal-title":"Am. J. Surg."},{"key":"BFnrneph201112_CR23","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ki.1988.99","volume":"33","author":"R Vanholder","year":"1988","unstructured":"Vanholder, R., Van Landschoot, N., De Smet, R., Schoots, A. & Ringoir, S. Drug protein binding in chronic renal failure: evaluation of nine drugs. Kidney Int. 33, 996\u20131004 (1988).","journal-title":"Kidney Int."},{"key":"BFnrneph201112_CR24","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1128\/AAC.00647-08","volume":"53","author":"JL Crandon","year":"2009","unstructured":"Crandon, J. L., Banevicius, M. A. & Nicolau, D. P. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob. Agents Chemother. 53, 1165\u20131169 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/00003246-199703000-00005","volume":"25","author":"A Meier-Hellman","year":"1997","unstructured":"Meier-Hellman, A. et al. Epinephrine impairs splanchnic perfusion in septic shock. Crit. Care Med. 25, 399\u2013404 (1997).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/cc7093","volume":"12","author":"AM Vilay","year":"2008","unstructured":"Vilay, A. M., Churchwell, M. D. & Mueller, B. A. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit. Care 12, 235 (2008).","journal-title":"Crit. Care"},{"key":"BFnrneph201112_CR27","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/S0272-6386(12)81089-4","volume":"21","author":"BA Mueller","year":"1993","unstructured":"Mueller, B. A., Scarim, S. K. & Macias, W. L. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am. J. Kidney Dis. 21, 172\u2013179 (1993).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201112_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/00003246-200003000-00005","volume":"28","author":"LJ Giles","year":"2000","unstructured":"Giles, L. J. et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit. Care Med. 28, 632\u2013637 (2000).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR29","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1097\/00003246-200010000-00006","volume":"28","author":"TF Ververs","year":"2000","unstructured":"Ververs, T. F. et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit. Care Med. 28, 3412\u20133416 (2000).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR30","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/clpt.1991.208","volume":"50","author":"WL Macias","year":"1991","unstructured":"Macias, W. L., Mueller, B. A. & Scarim, S. K. Vancomycin pharmacokinetics in acute renal failure: preservation of nonrenal clearance. Clin. Pharmacol. Ther. 50, 688\u2013694 (1991).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrneph201112_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1093\/jac\/dkl226","volume":"58","author":"F Pea","year":"2006","unstructured":"Pea, F., Poz, D., Viale, P., Pavan, F. & Furlanut, M. Which reliable pharmacodynamic breakpoint should be advised for ciprofloxacin monotherapy in the hospital setting? A TDM-based retrospective perspective. J. Antimicrob. Chemother. 58, 380\u2013386 (2006).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrneph201112_CR32","doi-asserted-by":"publisher","first-page":"997","DOI":"10.2165\/00003088-200746120-00003","volume":"46","author":"F Pea","year":"2007","unstructured":"Pea, F., Viale, P., Pavan, F. & Furlanut, M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin. Pharmacokinet. 46, 997\u20131038 (2007).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrneph201112_CR33","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1097\/01.ccm.0000281447.22966.8b","volume":"35","author":"C Schmidt","year":"2007","unstructured":"Schmidt, C., H\u00f6cherl, K., Schweda, F. & Bucher, M. Proinflammatory cytokines cause down-regulation of renal chloride entry pathways during sepsis. Crit. Care Med. 35, 2110\u20132119 (2007).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2005.05.010","volume":"109","author":"H Sun","year":"2006","unstructured":"Sun, H., Frassetto, L. & Benet, L. Z. Effects of renal failure on drug transport and metabolism. Pharmacol. Ther. 109, 1\u201311 (2006).","journal-title":"Pharmacol. Ther."},{"key":"BFnrneph201112_CR35","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.tips.2004.10.006","volume":"25","author":"H Miyazaki","year":"2004","unstructured":"Miyazaki, H., Sekine, T. & Endou, H. The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol. Sci. 25, 654\u2013662 (2004).","journal-title":"Trends Pharmacol. Sci."},{"key":"BFnrneph201112_CR36","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1093\/ndt\/gfi284","volume":"21","author":"R Bergner","year":"2006","unstructured":"Bergner, R. et al. Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800\u00a0mg. Nephrol. Dial. Transplant. 21, 1019\u20131023 (2006).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201112_CR37","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/MCC.0b013e3282f0a3d3","volume":"13","author":"M Schetz","year":"2007","unstructured":"Schetz, M. Drug dosing in continuous renal replacement therapy: general rules. Curr. Opin. Crit. Care 13, 645\u2013651 (2007).","journal-title":"Curr. Opin. Crit. Care"},{"key":"BFnrneph201112_CR38","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1053\/ajkd.1998.v31.pm9631848","volume":"31","author":"MS Joy","year":"1998","unstructured":"Joy, M. S., Matzke, G. R., Frye, R. F. & Palevsky, P. M. Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am. J. Kidney Dis. 31, 1019\u20131027 (1998).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201112_CR39","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1046\/j.1523-1755.56.s72.18.x","volume":"72","author":"WR Clark","year":"1999","unstructured":"Clark, W. R. & Ronco, C. CRRT efficiency and efficacy in relation to solute size. Kidney Int. Suppl. 72, S3\u2013S7 (1999).","journal-title":"Kidney Int. Suppl."},{"key":"BFnrneph201112_CR40","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1525-139X.2008.00541.x","volume":"22","author":"MD Churchwell","year":"2009","unstructured":"Churchwell, M. D. & Mueller, B. A. Drug dosing during continuous renal replacement therapy. Semin. Dial. 22, 185\u2013188 (2009).","journal-title":"Semin. Dial."},{"key":"BFnrneph201112_CR41","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00134-006-0397-x","volume":"32","author":"CS Bouman","year":"2006","unstructured":"Bouman, C. S. et al. Discrepancies between observed and predicted continuous venovenous hemofiltration removal of antimicrobial agents in critically ill patients and the effects on dosing. Intensive Care Med. 32, 2013\u20132019 (2006).","journal-title":"Intensive Care Med."},{"key":"BFnrneph201112_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1159\/000420197","volume":"93","author":"TA Golper","year":"1991","unstructured":"Golper, T. A. Drug removal during continuous hemofiltration or hemodialysis. Contrib. Nephrol. 93, 110\u2013116 (1991).","journal-title":"Contrib. Nephrol."},{"key":"BFnrneph201112_CR43","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","volume":"33","author":"S Uchino","year":"2007","unstructured":"Uchino, S. et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (BEST kidney) investigators. Intensive Care Med. 33, 1563\u20131570 (2007).","journal-title":"Intensive Care Med."},{"key":"BFnrneph201112_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1525-1594.1994.tb02228.x","volume":"18","author":"RF Jeffrey","year":"1994","unstructured":"Jeffrey, R. F. et al. A comparison of molecular clearance rates during continuous hemofiltration and hemodialysis with a novel volumetric continuous renal replacement system. Artif. Organs 18, 425\u2013428 (1994).","journal-title":"Artif. Organs"},{"key":"BFnrneph201112_CR45","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/039139880803100608","volume":"31","author":"Z Huang","year":"2008","unstructured":"Huang, Z., Letteri, J. J., Clark, W. R., Ronco, C. & Gao, D. Operational characteristics of continuous renal replacement modalities used for critically ill patients with acute kidney injury. Int. J. Artif. Organs 31, 525\u2013534 (2008).","journal-title":"Int. J. Artif. Organs"},{"key":"BFnrneph201112_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S0272-6386(12)70298-6","volume":"20","author":"CA DeSoi","year":"1992","unstructured":"DeSoi, C. A., Sahm, D. F. & Umans, J. G. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am. J. Kidney Dis. 20, 354\u2013360 (1992).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201112_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0272-6386(12)70321-9","volume":"22","author":"R Agarwal","year":"1993","unstructured":"Agarwal, R. & Toto, R. D. Gentamicin clearance during hemodialysis: a comparison of high-efficiency cuprammonium rayon and conventional cellulose ester hemodialyzers. Am. J. Kidney Dis. 22, 296\u2013299 (1993).","journal-title":"Am. J. Kidney Dis."},{"key":"BFnrneph201112_CR48","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1093\/ndt\/12.12.2647","volume":"12","author":"MK Scott","year":"1997","unstructured":"Scott, M. K., Mueller, B. A. & Clark, W. R. Vancomycin mass transfer characteristics of high-flux cellulosic dialysers. Nephrol. Dial. Transplant. 12, 2647\u20132653 (1997).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201112_CR49","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1177\/001857870403900208","volume":"39","author":"JW Ahern","year":"2004","unstructured":"Ahern, J. W., Lai, C., Rebuck, J. A., Possidente, C. J. & Weidner, M. Experience with vancomycin in patients receiving slow low efficiency dialysis. Hosp. Pharm. 39, 138\u2013143 (2004).","journal-title":"Hosp. Pharm."},{"key":"BFnrneph201112_CR50","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1097\/01.CCM.0000147687.06808.92","volume":"32","author":"E Fiaccadori","year":"2004","unstructured":"Fiaccadori, E. et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit. Care Med. 32, 2437\u20132442 (2004).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR51","first-page":"468","volume":"24","author":"G Choi","year":"2004","unstructured":"Choi, G. et al. The effect of adsorption, filter material and point of dilution on antibiotic elimination by haemofiltration: an in vitro study of levofloxacin. Int. J. Antimicrob. Agents 24, 468\u2013472 (2004).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFnrneph201112_CR52","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ijantimicag.2006.03.025","volume":"28","author":"Q Tian","year":"2006","unstructured":"Tian, Q. et al. Effect of drug concentration on adsorption of levofloxacin by polyacrylonitrile haemofilters. Int. J. Antimicrob. Agents 28, 147\u2013150 (2006).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFnrneph201112_CR53","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s00134-002-1495-z","volume":"28","author":"S Uchino","year":"2002","unstructured":"Uchino, S., Cole, L., Morimatsu, H., Goldsmith, D. & Bellomo, R. Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med. 28, 1664\u20131667 (2002).","journal-title":"Intensive Care Med."},{"key":"BFnrneph201112_CR54","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1046\/j.1525-1594.2003.07288.x","volume":"27","author":"WR Clark","year":"2003","unstructured":"Clark, W. R., Turk, J. E., Kraus, M. A. & Gao, D. Dose determinants in continuous renal replacement therapy. Artif. Organs 27, 815\u2013820 (2003).","journal-title":"Artif. Organs"},{"key":"BFnrneph201112_CR55","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1046\/j.1525-1594.2003.07283.x","volume":"27","author":"BA Mueller","year":"2003","unstructured":"Mueller, B. A., Pasko, D. A. & Sowinski, K. M. Higher renal replacement therapy dose delivery influences on drug therapy. Artif. Organs 27, 808\u2013814 (2003).","journal-title":"Artif. Organs"},{"key":"BFnrneph201112_CR56","volume-title":"Drug prescribing in renal failure: dosing guidelines for adults and children","author":"GR Aronoff","year":"2007","unstructured":"Aronoff, G. R. et al. Drug prescribing in renal failure: dosing guidelines for adults and children 5th edn (American College of Physicians, Philadelphia, 2007)."},{"key":"BFnrneph201112_CR57","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/510079","volume":"44","author":"PG Ambrose","year":"2007","unstructured":"Ambrose, P. G. et al. Pharmacokinetics: pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44, 79\u201386 (2007).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrneph201112_CR58","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.2146\/090087d","volume":"66","author":"RC Owens Jr","year":"2009","unstructured":"Owens, R. C. Jr & Shorr, A. F. Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies. Am. J. Health Syst. Pharm. 66, S23\u2013S30 (2009).","journal-title":"Am. J. Health Syst. Pharm."},{"key":"BFnrneph201112_CR59","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1086\/652767","volume":"50","author":"SM Bhavnani","year":"2010","unstructured":"Bhavnani, S. M., Rubino, C. M., Ambrose, P. G. & Drusano, G. L. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin. Infect. Dis. 50, 1568\u20131574 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrneph201112_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/CCM.0b013e3181fa36fb","volume":"39","author":"AM Vilay","year":"2011","unstructured":"Vilay, A. M. et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit. Care Med. 39, 19\u201325 (2011).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR61","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1159\/000097078","volume":"24","author":"MD Churchwell","year":"2006","unstructured":"Churchwell, M. D., Pasko, D. A. & Mueller, B. A. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif. 24, 548\u2013554 (2006).","journal-title":"Blood Purif."},{"key":"BFnrneph201112_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0891-5520(03)00057-6","volume":"17","author":"J Turnidge","year":"2003","unstructured":"Turnidge, J. Pharmacodynamics and dosing of aminoglycosides. Infect. Dis. Clin. North Am. 17, 503\u2013528 (2003).","journal-title":"Infect. Dis. Clin. North Am."},{"issue":"Suppl. C","key":"BFnrneph201112_CR63","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/jac\/27.suppl_C.91","volume":"27","author":"G Beaucaire","year":"1991","unstructured":"Beaucaire, G. et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J. Antimicrob. Chemother. 27 (Suppl. C), 91\u2013103 (1991).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrneph201112_CR64","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/jac\/28.5.753","volume":"28","author":"PE Marik","year":"1991","unstructured":"Marik, P. E., Lipman, J., Kobilski, S. & Scribante, J. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J. Antimicrob. Chemother. 28, 753\u2013764 (1991).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrneph201112_CR65","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1093\/ndt\/gfp704","volume":"25","author":"JT Kielstein","year":"2010","unstructured":"Kielstein, J. T. et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis\u2014a pharmacokinetic study. Nephrol. Dial. Transplant. 25, 1537\u20131541 (2010).","journal-title":"Nephrol. Dial. Transplant."},{"key":"BFnrneph201112_CR66","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1345\/aph.1M339","volume":"44","author":"J Perrott","year":"2010","unstructured":"Perrott, J., Mabasa, V. H. & Ensom, M. H. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann. Pharmacother. 44, 557\u2013564 (2010).","journal-title":"Ann. Pharmacother."},{"key":"BFnrneph201112_CR67","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00134-008-1034-7","volume":"34","author":"J Langgartner","year":"2008","unstructured":"Langgartner, J., Vasold, A., Gl\u00fcck, T., Reng, M. & Kees, F. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 34, 1091\u20131096 (2008).","journal-title":"Intensive Care Med."},{"key":"BFnrneph201112_CR68","doi-asserted-by":"publisher","first-page":"R26","DOI":"10.1186\/cc3993","volume":"10","author":"C Mariat","year":"2006","unstructured":"Mariat, C. et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit. Care 10, R26 (2006).","journal-title":"Crit. Care"},{"key":"BFnrneph201112_CR69","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.ijantimicag.2010.06.008","volume":"36","author":"JA Roberts","year":"2010","unstructured":"Roberts, J. A. et al. Therapeutic drug monitoring of \u03b2-lactams in critically ill patients: proof of concept. Int. J. Antimicrob. Agents 36, 332\u2013339 (2010).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"BFnrneph201112_CR70","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/MCC.0b013e3282f0a3d3","volume":"13","author":"M Schetz","year":"2007","unstructured":"Schetz, M. Drug dosing in continuous renal replacement therapy: general rules. Curr. Opin. Crit. Care 13, 645\u2013651 (2007).","journal-title":"Curr. Opin. Crit. Care"},{"key":"BFnrneph201112_CR71","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000321488","volume":"30","author":"G Choi","year":"2010","unstructured":"Choi, G. et al. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif. 30, 195\u2013212 (2010).","journal-title":"Blood Purif."},{"key":"BFnrneph201112_CR72","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2165\/00003088-199324050-00002","volume":"24","author":"P Reetze-Bonorden","year":"1993","unstructured":"Reetze-Bonorden, P., B\u00f6hler, J. & Keller, E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin. Pharmacokinet. 24, 362\u2013379 (1993).","journal-title":"Clin. Pharmacokinet."},{"key":"BFnrneph201112_CR73","first-page":"748","volume":"3","author":"UF Kroh","year":"1995","unstructured":"Kroh, U. F. Drug administration in critically ill patients with acute renal failure. New Horiz. 3, 748\u2013759 (1995).","journal-title":"New Horiz."},{"key":"BFnrneph201112_CR74","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/clpt.2009.150","volume":"86","author":"BA Mueller","year":"2009","unstructured":"Mueller, B. A. & Smoyer, W. E. Challenges in developing evidence-based drug dosing guidelines for adults and children receiving renal replacement therapy. Clin. Pharmacol. Ther. 86, 479\u2013482 (2009).","journal-title":"Clin. Pharmacol. Ther."},{"key":"BFnrneph201112_CR75","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/jac\/dkp302","volume":"64","author":"AM Li","year":"2009","unstructured":"Li, A. M. et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J. Antimicrob. Chemother. 64, 929\u2013937 (2009).","journal-title":"J. Antimicrob. Chemother."},{"key":"BFnrneph201112_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF01977494","volume":"3","author":"W Wingender","year":"1984","unstructured":"Wingender, W. et al. Pharmacokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur. J. Clin. Microbiol. 3, 355\u2013359 (1984).","journal-title":"Eur. J. Clin. Microbiol."},{"key":"BFnrneph201112_CR77","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/j.1875-9114.1995.tb04359.x","volume":"15","author":"DN Fish","year":"1995","unstructured":"Fish, D. N., Bainbridge, J. L. & Peloquin, C. A. Variable disposition of ciprofloxacin in critically ill patients undergoing continuous arteriovenous hemodiafiltration. Pharmacotherapy 15, 236\u2013245 (1995).","journal-title":"Pharmacotherapy"},{"key":"BFnrneph201112_CR78","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s001340100857","volume":"27","author":"SC Wallis","year":"2001","unstructured":"Wallis, S. C., Mullany, D. V., Lipman, J., Rickard, C. M. & Daley, P. J. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous hemodiafiltration. Intensive Care Med. 27, 665\u2013672 (2001).","journal-title":"Intensive Care Med."},{"key":"BFnrneph201112_CR79","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1128\/AAC.41.10.2256","volume":"41","author":"SC Chien","year":"1997","unstructured":"Chien, S. C. et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41, 2256\u20132260 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR80","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1128\/AAC.45.7.2122-2125.2001","volume":"45","author":"AT Chow","year":"2001","unstructured":"Chow, A. T. et al. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob. Agents Chemother. 45, 2122\u20132125 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR81","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1128\/AAC.45.10.2949-2954.2001","volume":"45","author":"RS Malone","year":"2001","unstructured":"Malone, R. S., Fish, D. N., Abraham, E. & Teitelbaum, I. Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients. Antimicrob. Agents Chemother. 45, 2949\u20132954 (2001).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR82","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1592\/phco.22.3.175.33546","volume":"22","author":"SG Guenter","year":"2002","unstructured":"Guenter, S. G., Iven, H., Boos, C., Bruch, H. P. & Muhl, E. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy 22, 175\u2013183 (2002).","journal-title":"Pharmacotherapy"},{"key":"BFnrneph201112_CR83","doi-asserted-by":"publisher","first-page":"S316","DOI":"10.1093\/infdis\/135.Supplement_2.S316","volume":"134","author":"H Lode","year":"1976","unstructured":"Lode, H., Grunert, K., Koeppe, K. P. & Langmaack, H. Pharmacokinetic and clinical studies with amikacin, a new aminoglycoside antibiotic. J. Infect. Dis. 134, S316\u2013S322 (1976).","journal-title":"J. Infect. Dis."},{"key":"BFnrneph201112_CR84","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1128\/AAC.37.3.464","volume":"37","author":"JM Kinowski","year":"1993","unstructured":"Kinowski, J. M. et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob. Agents Chemother. 37, 464\u2013473 (1993).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR85","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1128\/AAC.00247-06","volume":"50","author":"M Benvenuto","year":"2006","unstructured":"Benvenuto, M., Benziger, D. P., Yankelev, S. & Vigliani, G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob. Agents Chemother. 50, 3245\u20133249 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR86","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/BF01964413","volume":"10","author":"I Nilsson-Ehle","year":"1991","unstructured":"Nilsson-Ehle, I., Hutchison, M., Haworth, S. J. & Norrby, S. R. Pharmacokinetics of meropenem compared to imipenem\u2013cilastatin in young, healthy males. Eur. J. Clin. Microbiol. Infect. Dis. 10, 85\u201388 (1991).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"BFnrneph201112_CR87","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1128\/AAC.49.5.1881-1889.2005","volume":"49","author":"WA Krueger","year":"2005","unstructured":"Krueger, W. A. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob. Agents Chemother. 49, 1881\u20131889 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR88","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1128\/AAC.40.1.105","volume":"40","author":"M Dreetz","year":"1996","unstructured":"Dreetz, M. et al. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem\u2013cilastatin. Antimicrob. Agents Chemother. 40, 105\u2013109 (1996).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR89","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1128\/AAC.42.9.2421","volume":"42","author":"WA Krueger","year":"1998","unstructured":"Krueger, W. A. et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob. Agents Chemother. 42, 2421\u20132424 (1998).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR90","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1128\/AAC.41.11.2511","volume":"41","author":"DJ Occhipinti","year":"1997","unstructured":"Occhipinti, D. J. et al. Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin\u2013tazobactam regimens. Antimicrob. Agents Chemother. 41, 2511\u20132517 (1997).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR91","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1097\/00003246-199801000-00021","volume":"26","author":"G Capellier","year":"1998","unstructured":"Capellier, G. et al. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit. Care Med. 26, 88\u201391 (1998).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR92","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s001340050424","volume":"23","author":"TS van der Werf","year":"1997","unstructured":"van der Werf, T. S., Mulder, P. O., Zijlstra, J. G., Uges, D. R. & Stegeman, C. A. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med. 23, 873\u2013877 (1997).","journal-title":"Intensive Care Med."},{"key":"BFnrneph201112_CR93","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1128\/AAC.21.4.575","volume":"21","author":"RA Blouin","year":"1982","unstructured":"Blouin, R. A., Bauer, L. A., Miller, D. D., Record, K. E. & Griffen, W. O. Jr. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob. Agents Chemother. 21, 575\u2013580 (1982).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR94","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1128\/AAC.31.3.393","volume":"31","author":"DP Healy","year":"1987","unstructured":"Healy, D. P., Polk, R. E., Garson, M. L., Rock, D. T. & Comstock, T. J. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob. Agents Chemother. 31, 393\u2013397 (1987).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR95","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1128\/AAC.32.1.92","volume":"32","author":"M Boeckh","year":"1988","unstructured":"Boeckh, M. et al. Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers. Antimicrob. Agents Chemother. 32, 92\u201395 (1988).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrneph201112_CR96","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/01.CCM.0000190243.88133.3F","volume":"34","author":"JT Kielstein","year":"2006","unstructured":"Kielstein, J. T. et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med. 34, 51\u201356 (2006).","journal-title":"Crit. Care Med."},{"key":"BFnrneph201112_CR97","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1365-2125.2004.02143.x","volume":"58","author":"ME DelDot","year":"2004","unstructured":"DelDot, M. E., Lipman, J. & Tett, S. E. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br. J. Clin. Pharmacol. 58, 259\u2013268 (2004).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"BFnrneph201112_CR98","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1086\/444500","volume":"41","author":"RL Trotman","year":"2005","unstructured":"Trotman, R. L., Williamson, J. C., Shoemaker, D. M. & Salzer, W. L. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin. Infect. Dis. 41, 1159\u20131166 (2005).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrneph201112_CR99","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1592\/phco.29.5.562","volume":"29","author":"BH Heintz","year":"2009","unstructured":"Heintz, B. H., Matzke, G. R. & Dager, W. E. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 29, 562\u2013577 (2009).","journal-title":"Pharmacotherapy"},{"key":"BFnrneph201112_CR100","unstructured":"Gilbert, D. N. (Ed.) The Sanford Guide to Antimicrobial Therapy 40th edn (Sanford, Sperryville, 2010)."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2011.12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2011.12","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrneph.2011.12.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T12:02:56Z","timestamp":1712232176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrneph.2011.12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,22]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["BFnrneph201112"],"URL":"https:\/\/doi.org\/10.1038\/nrneph.2011.12","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,22]]}}}